Atricure reports preliminary results for fourth quarter and full year 2021, provides financial outlook for 2022

Mason, ohio--(business wire)--atricure, inc. (nasdaq: atrc), a leading innovator in surgical treatments and therapies for atrial fibrillation (afib), left atrial appendage (laa) management, and post-operative pain management, announced preliminary financial results for the fourth quarter and full year 2021 and provided 2022 financial guidance. preliminary, unaudited revenue for fourth quarter 2021 is expected to be approximately $73.2 million, reflecting growth of approximately 27% over the fou
ATRC Ratings Summary
ATRC Quant Ranking